One Eleven Interactive, Inc

Innovative marketing programs for the pharmaceutical industry

One Eleven Interactive, Inc Introduction FDA: Ampio Pharmaceuticals stock down 7% due to opioid shortages

FDA: Ampio Pharmaceuticals stock down 7% due to opioid shortages



Pharmaceuticals company Ampio is down 7 percent on Tuesday, citing shortages of opiate-based drugs.

The company said it expects to begin a phased-in program next month to distribute the drugs.

The company said the shortage has resulted in shortages of Opana, a painkiller and an injectable opioid, and several other painkiller products.

It expects the number of Oplanas manufactured to decrease.

Ampio’s stock price has fallen more than 50 percent in the past two years as the drugmaker struggles to turn a profit.

The opioid crisis has led to the opioid-related deaths of more than 4,200 people in the U.S. since the beginning of 2017, according to data from the Centers for Disease Control and Prevention.

A similar number of deaths have been caused by the opioid use in the last year, the CDC said.

A number of major U..

S.-based drugmakers have been forced to pull their products from the market in recent years because of soaring opioid-use deaths.

Some companies have reported sales growth from the drug’s decline.

The drugmaker also said it was suspending its development and manufacturing of a pain reliever called Narcan, which can reverse overdoses.

TopBack to Top